Why Your ADHD Medication Stopped Working: The Estrogen-Dopamine Connection · Ayden Miller
Why Your ADHD Medication Stopped Working: The Estrogen-Dopamine Connection
Published by Finally. | Research & Science
You were managing. Maybe not perfectly, but you had systems. The medication helped. You knew your brain, you had built a life around how it worked, and then somewhere down the line, you felt changes. The Adderall that used to carry you through a full workday started wearing off by noon. The Vyvanse that once felt like clarity started feeling like a drop in the ocean. Upping the dose will work, sure. For now, but how long until you need to get it increased? Then again? Do you need to wait for it to stop working or look for a new solution?
Nobody told you this was coming, not on top of the heat flashes and 3am wakeups. Who would tie together the same reason that you were unable to pull a word from your brain in the middle of a sentence would be the same reason you needed to leave a book on your pillow to make sure you would read before bed.
You may have suspected it. But you never had the biology to tie it together so your doctor could see through the same lens as you. Here is what you've been feeling.
Estrogen Is Not a Reproductive Hormone. It Is a Brain Hormone.
This is the framing error that leaves most women without answers. Estrogen is classified and discussed primarily in the context of reproduction, which means that when reproduction winds down, the medical conversation about estrogen winds down with it. Your OB-GYN focuses on menstrual cycles and hot flashes. Your psychiatrist focuses on your ADHD symptoms. Nobody is sitting at the intersection, looking at what estrogen was doing to your brain before it started declining.
Estrogen receptors are distributed throughout the central nervous system. They are found in the prefrontal cortex, the hippocampus, the amygdala, and critically, in the dopaminergic pathways that run through the brain's reward and executive function systems (McEwen et al., 2012). Estrogen is not a visitor in these regions. It is a structural participant in how they function.
The relationship between estrogen and dopamine is not incidental. Estradiol, the most potent form of estrogen and the one that declines most sharply during perimenopause, does several things to dopamine simultaneously:
It stimulates dopamine synthesis in the prefrontal cortex. It slows dopamine breakdown by inhibiting the enzyme monoamine oxidase B (MAO-B). It upregulates dopamine receptor density, specifically D1 and D2 receptors, in regions governing attention, working memory, and impulse control. And it enhances dopamine transporter function, regulating how efficiently dopamine is recycled at the synapse (Dluzen & Bhatt, 2008; Yoest et al., 2014).
What this means practically: when estradiol is present at healthy premenopausal levels, the dopaminergic system runs with a degree of structural support that most women never notice because it has always been there. The medication works. The coping strategies work. The systems you built hold.
When estradiol starts declining in perimenopause, that structural support begins to erode. Not immediately, not catastrophically, but progressively. The scaffolding comes down slowly enough that the connection is rarely made.
What ADHD Looks Like on a Dopamine System That Is Losing Its Scaffolding
Attention deficit hyperactivity disorder is fundamentally a disorder of dopamine regulation in the prefrontal cortex. The current neurobiological consensus is that ADHD involves reduced dopaminergic tone in circuits governing executive function, working memory, sustained attention, and impulse inhibition (Arnsten, 2006; Faraone et al., 2021).
Stimulant medications work by increasing the availability of dopamine and norepinephrine at the synapse. They do not fix the underlying architecture. They compensate for it by flooding the system with more neurotransmitter than it would otherwise have available.
Now consider what happens when the system that was quietly supporting your dopamine signaling for three decades begins to withdraw.
The stimulant dose that was adequate when estradiol was providing structural reinforcement is no longer adequate when that reinforcement is gone. The medication has not changed. The baseline it is compensating for has changed. You need more stimulant to achieve the same functional outcome, not because your ADHD has gotten worse, but because the hormonal environment that was quietly helping manage it has shifted underneath you.
Physicians who are not tracking this intersection will typically respond to medication failure in perimenopause by adjusting the dose upward, changing the formulation, or reconsidering the diagnosis. What they should be asking is: what changed around the time this stopped working? In many women, the answer is that perimenopause started.
The Late Diagnosis Problem
There is a related issue that deserves its own discussion. Many women in their 40s are being diagnosed with ADHD for the first time, not because they did not have it previously, but because they were previously managing it without knowing that is what they were doing.
Research consistently shows that ADHD is underdiagnosed in girls and women relative to boys and men (Quinn & Madhoo, 2014). Girls with ADHD tend to present with inattentive rather than hyperactive symptoms, develop more robust compensatory strategies, and are less likely to be flagged in clinical or educational settings. Many spend decades being described as bright but disorganized, or capable but scattered, or sensitive and prone to anxiety, without anyone looking at the underlying neurology.
What held the compensatory strategies together, in many cases, was estradiol. High-performing women with undiagnosed ADHD frequently describe their late 30s and early 40s as a period of maximum capacity. They had decades of practiced coping mechanisms, and they had robust estrogen levels supporting their dopamine system. When perimenopause arrives and estradiol begins its decline, the compensatory strategies start failing. Executive dysfunction that was previously managed through structure, habit, and sheer cognitive effort becomes unmanageable. Women who never struggled significantly in professional environments suddenly cannot complete tasks, cannot maintain focus through a meeting, cannot hold a train of thought long enough to finish a sentence.
This is when the diagnosis comes. The first ADHD diagnosis in a 47-year-old woman is frequently not a case of ADHD appearing in midlife. It is a case of ADHD becoming visible in midlife because the hormonal buffer that was masking it has been withdrawn.
The NAD+ Layer
The estrogen-dopamine relationship is not the only mechanism at work here. There is a second pathway that compounds the cognitive impairment, and it runs through cellular energy metabolism.
Nicotinamide adenine dinucleotide, or NAD+, is the coenzyme your cells use to produce ATP, the energy currency of the body. NAD+ is present in every cell and is essential to mitochondrial function, DNA repair, and cellular resilience. It declines with age, but the rate of that decline accelerates significantly during perimenopause through a specific enzyme-mediated mechanism.
CD38 is an enzyme that consumes NAD+. It is involved in immune signaling and calcium regulation, and under normal circumstances its activity is modulated by several factors, including estrogen. When estradiol levels decline, CD38 activity is upregulated (Camacho-Pereira et al., 2016). More CD38 means more NAD+ consumed. More NAD+ consumed means less available for mitochondrial energy production. Less mitochondrial energy production in the brain means neurons that are already under dopaminergic stress are now also running on reduced cellular fuel.
The prefrontal cortex, the region most implicated in ADHD and executive function, is among the most metabolically demanding regions in the brain. It requires sustained, reliable ATP production to maintain the neuronal activity that supports working memory, attention, and cognitive control. When NAD+ depletion reduces the mitochondria's capacity to produce ATP at the required rate, prefrontal function is among the first to degrade.
This is not a separate problem from the dopamine issue. It is the same problem at a different level of biology. The dopaminergic scaffolding is being withdrawn by estrogen decline. The cellular energy supply is being reduced by NAD+ depletion. Both are happening simultaneously, driven by the same underlying hormonal shift. The result is a cognitive system that is being squeezed from two directions at once.
Yoshino et al. (2021) conducted the first randomized controlled trial of NMN supplementation specifically in perimenopausal and postmenopausal women, published in Science. The study found that NMN supplementation at 250mg per day for 10 weeks increased skeletal muscle NAD+ levels and improved insulin sensitivity, suggesting that NAD+ restoration through precursor supplementation is achievable in this population. The cognitive implications of sustained NAD+ restoration in this demographic remain an active area of research, but the metabolic findings establish the baseline: NAD+ depletion in perimenopausal women is real, measurable, and responsive to precursor intervention.
The Dopamine-NAD+ Intersection in Executive Function
Dopamine synthesis itself is an energy-dependent process. The enzymes involved in converting tyrosine to dopamine, including tyrosine hydroxylase and DOPA decarboxylase, require cofactors and cellular energy to function (Meiser et al., 2013). A neuron that is low on NAD+ and producing insufficient ATP is a neuron that cannot synthesize dopamine efficiently regardless of how much precursor substrate is available.
This creates a compounding failure loop. Estrogen decline reduces dopaminergic tone directly through receptor downregulation and reduced synthesis stimulation. Estrogen decline also accelerates NAD+ depletion through CD38 upregulation. Reduced NAD+ impairs the cellular energy supply neurons need to synthesize dopamine efficiently. The result is a dopamine system that is under-supported at the structural level and under-resourced at the metabolic level simultaneously.
Stimulant medications address neither of these root causes. They compensate for reduced dopamine availability by increasing synaptic dopamine concentrations through reuptake inhibition or increased release. But if the neurons themselves are less capable of producing dopamine due to metabolic constraint, and if the receptor environment is less sensitive due to reduced estradiol support, the stimulant is working against a structural deficit it was not designed to address.
Why This Is Not in Your Doctor's Head
The 2019 North American Menopause Society position statement notes that physician knowledge of menopause management is inconsistent and frequently inadequate, with surveys suggesting that fewer than 7% of residents in relevant specialties feel prepared to support menopausal patients (Kling et al., 2019).
The ADHD side of this picture is equally fragmented. Psychiatric training in ADHD has historically centered on pediatric populations and adult males. The presentation of ADHD in adult women, particularly the inattentive subtype that predominates in female patients, has received comparatively little attention in clinical training curricula (Quinn & Madhoo, 2014). The intersection of hormonal transition and ADHD neurobiology is a subject that falls between specialties. Your psychiatrist is not thinking about your estradiol levels. Your OB-GYN is not thinking about your dopamine receptors. The result is that the connection between perimenopausal hormonal change and ADHD symptom exacerbation is missed in the vast majority of clinical encounters.
This is not a failure of individual physicians. It is a structural gap in how medicine has historically organized its knowledge about women's health across the lifespan. Research by Saltz (2025), published in Frontiers in Psychology, documents the phenomenon of age-related gendered diminishment in post-midlife women, describing the psychological consequences of a medical and social system that consistently fails to prepare women for or adequately support them through the cognitive and emotional changes of the menopausal transition.
What the Research Actually Supports
The direct research on estrogen-ADHD interactions in perimenopausal women is, frankly, thin. This is consistent with the broader pattern of underinvestment in female-specific neurology and women's health research that Criado Perez (2019) documented extensively in her analysis of how medical research has treated women as default male bodies with hormonal variation.
What the research does support clearly:
Estradiol modulates dopamine synthesis, receptor expression, and metabolic efficiency in the prefrontal cortex and striatum (McEwen et al., 2012; Yoest et al., 2014). Dopaminergic dysregulation is the primary neurobiological mechanism of ADHD (Faraone et al., 2021). NAD+ depletion during perimenopause is mediated by estrogen withdrawal and CD38 upregulation (Camacho-Pereira et al., 2016). Dopamine synthesis is metabolically dependent on cellular energy availability (Meiser et al., 2013). NMN supplementation can restore NAD+ levels in perimenopausal and postmenopausal women (Yoshino et al., 2021).
The mechanistic chain connecting these findings is coherent and consistent with the clinical experience reported by large numbers of perimenopausal women with ADHD. The absence of clinical trials specifically testing ADHD symptom outcomes in the context of estrogen-NAD+ restoration does not mean the connection does not exist. It means the research has not yet caught up to the biology.
What This Means Practically
If your ADHD medication stopped working in your 40s, the first questions worth asking are not about dose adjustments or alternative stimulant formulations. They are about what changed in your hormonal and metabolic environment around the time the medication started failing.
Hormone replacement therapy, where appropriate and accessible, addresses the estradiol component of this picture directly. The research on HRT and cognitive function in perimenopausal women is extensive and generally supportive, particularly for women who initiate HRT within the critical window around the onset of perimenopause (Kling et al., 2019). This is a conversation worth having with a physician who understands perimenopause and is not dismissive of the cognitive symptoms.
The NAD+ component is addressable through precursor supplementation. NMN and nicotinamide riboside (NR) both serve as precursors to NAD+ through different metabolic pathways, and both have been studied in the context of NAD+ restoration in aging populations (Yoshino et al., 2021; Trammell et al., 2016). The relevant consideration in the context of perimenopause is targeting the specific depletion mechanism: it is not simply that NAD+ declines with age, but that estrogen withdrawal accelerates that decline through CD38 upregulation, creating a depletion rate that exceeds what normal aging would produce.
This is why generic NAD+ supplements marketed for aging do not specifically serve this demographic. The mechanism is not generic age-related NAD+ decline. It is hormonally mediated, enzyme-driven, and specific to the estrogen withdrawal of perimenopause.
The final practical point is the most important one. If you have spent months or years describing these cognitive changes to physicians who attributed them to stress, anxiety, normal aging, or depression, you are not the exception. You are the rule. The medical system has not been adequately prepared to see the intersection of hormonal transition and neurodevelopmental variation in adult women. The absence of a diagnosis or explanation does not mean there is no biological basis for what you are experiencing. The biology is well established. The clinical awareness has not kept pace with it.
References
Arnsten, A. F. T. (2006). Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways. Journal of Clinical Psychiatry, 67(Suppl 8), 7-12.
Camacho-Pereira, J., Tarrago, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., Puranik, A. S., Schoon, R. A., Reid, J. M., Galina, A., & Chini, E. N. (2016). CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 23(6), 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006
Criado Perez, C. (2019). Invisible women: Exposing data bias in a world designed for men. Chatto & Windus.
Dluzen, D. E., & Bhatt, S. (2008). Effects of estrogen and the 5-HT3 receptor on dopamine-stimulated methamphetamine-induced changes in locomotor behavior. Neuropharmacology, 55(2), 140-147. https://doi.org/10.1016/j.neuropharm.2008.05.006
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., Rohde, L. A., Yang, L., Cortese, S., Almagor, D., Stein, M. A., Albatti, T. H., Aljoudi, H. F., Alqahtani, M. M. J., Asherson, P., ... Wang, Y. (2021). The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789-818. https://doi.org/10.1016/j.neubiorev.2021.01.022
Kling, J. M., MacLaughlin, K. L., Schnatz, P. F., Crandall, C. J., Skinner, L. J., Bhagra, A., & Faubion, S. S. (2019). Menopause management knowledge in postgraduate family medicine, internal medicine, and obstetrics and gynecology residents: A cross-sectional survey. Mayo Clinic Proceedings, 94(2), 242-253. https://doi.org/10.1016/j.mayocp.2018.08.033
McEwen, B. S., Akama, K. T., Spencer-Segal, J. L., Milner, T. A., & Waters, E. M. (2012). Estrogen effects on the brain: Actions beyond the hypothalamus via novel mechanisms. Behavioral Neuroscience, 126(1), 4-16. https://doi.org/10.1037/a0026708
Meiser, J., Weindl, D., & Hiller, K. (2013). Complexity of dopamine metabolism. Cell Communication and Signaling, 11(1), 34. https://doi.org/10.1186/1478-811X-11-34
Quinn, P. O., & Madhoo, M. (2014). A review of attention-deficit/hyperactivity disorder in women and girls: Uncovering this hidden diagnosis. The Primary Care Companion for CNS Disorders, 16(3). https://doi.org/10.4088/PCC.13r01596
Saltz, R. (2025). Age-related gendered diminishment: Toward understanding and interventions for a common psychological experience in post-midlife women. Frontiers in Psychology, 16, 1535145. https://doi.org/10.3389/fpsyg.2025.1535145
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jakobsson, A., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications, 7, 12948. https://doi.org/10.1038/ncomms12948
Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., Sindelar, M., Pietka, T., Patterson, B. W., Imai, S., & Klein, S. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. https://doi.org/10.1126/science.abe9985
Yoest, K. E., Cummings, J. A., & Becker, J. B. (2014). Estradiol, dopamine and motivation. Central Nervous System Agents in Medicinal Chemistry, 14(2), 83-89. https://doi.org/10.2174/1871524914666141226103135